Why the study?
The use of NSAIDs for acute and chronic pain carries potential risks of complications, requiring an assessment of adverse cardiovascular reactions and approaches to reduce them.
How do NSAIDs affect cardiovascular safety, and how can these adverse reactions be minimized based on patient cardiovascular risk profiles?
How do NSAIDs affect cardiovascular safety, and how can these adverse reactions be minimized based on patient cardiovascular risk profiles?
This review emphasizes the necessity of personalizing NSAID prescriptions based on a patient's total cardiovascular risk to mitigate severe adverse cardiovascular events.
Risk-stratified NSAID selection may minimize CV events; leaves open prospective trial confirmation.
The most important issue of modern pharmacotherapy is not only efficacy, but also the safety of medicines. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is one of the main methods of treating acute and chronic pain in a wide range of diseases and pathological conditions. However, the prescription of this group of drugs requires consideration of the potential risks of complications, including from the side of the cardiovascular system. The purpose of the review was to assess the adverse reactions of the cardiovascular system when taking NSAIDs and approaches to their reduction. The article presents data on the mutual potential impact of cardiovascular diseases and musculoskeletal system, presents the results of large-scale studies of Russian and foreign authors and meta-analyzes of the NSAIDs effect on blood pressure profile, development of myocardial infarction, stroke and heart failure. The possible pathogenetic mechanisms of the side effects of NSAIDs are reviewed; the complexity of managing comorbid patients is demonstrated; it is shown that symptomatic treatment of pain and inflammatory syndrome should be carried out considering a personalized approach to the patient and rational choice of drugs. Before the NSAIDs prescription, it is necessary to consider all cardiovascular risk factors with the determination of the total risk of cardiovascular complications. In patients with a very high cardiovascular risk, the use of any NSAIDs should be avoided; with high and moderate risk, the use of NSAIDs with the most favorable cardiovascular safety profile is possible. If the patient belongs to the category of low total coronary risk, the doctor can choose any NSAIDs.
No takes yet. Share an insight, caveat, or question.
Пырикова et al. (2019) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: